|
Jul 15
|
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
|
|
Jul 15
|
Health Canada extends Evkeeza approval for children with HoFH
|
|
Jul 15
|
1 Healthcare Stock on Our Buy List and 2 to Brush Off
|
|
Jul 14
|
Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence
|
|
Jul 14
|
Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments
|
|
Jul 14
|
Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape
|
|
Jul 11
|
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
|
|
Jul 10
|
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
|
|
Jul 10
|
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
|
|
Jul 9
|
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
|
|
Jul 3
|
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
|
|
Jul 2
|
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
|
|
Jul 2
|
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
|
|
Jul 1
|
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
|
|
Jul 1
|
Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million
|
|
Jun 30
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices
|
|
Jun 30
|
Former 23andMe CEO regains company control as $305m sale to nonprofit approved
|
|
Jun 30
|
Circle initiated, Disney upgraded: Wall Street's top analyst calls
|
|
Jun 26
|
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
|
|
May 27
|
3 Value Stocks with Questionable Fundamentals
|